Sorry America, but it's not Australia's fault that your healthcare system is failing you
Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries.
This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes.
Sign up: AU Breaking News email
And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic.
There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse.
It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US.
The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists.
And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US.
This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe.
More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector.
But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory.
The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange.
John Quiggin is a professor at the University of Queensland's school of economics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ITV News
37 minutes ago
- ITV News
A third of GP appointments in June were over the phone or online, data shows
A third (33.3%) of GP appointments in England in June were carried out either over the phone or online, the highest proportion since the pandemic. The figure is up from 30.9% a year earlier in June 2024, and 28.3% in June 2023, according to new analysis of NHS England data by the PA news agency. Family doctors said remote consultations 'offer convenience and flexibility that many patients value', and the majority of appointments are still delivered face to face. As many as four in 10 appointments were carried out by phone or online during the pandemic, but the proportion fell once the impact of Covid-19 eased and had dropped to 27.7% in January 2023. In the past two years the figure has risen slowly but steadily, driven by a sharp increase in consultations taking place online. These accounted for only 1.5% of all GP appointments in June 2023 but had jumped to 4.9% by June 2024 and 8.0% in June this year. This has helped push up the combined figure for phone and online appointments to its current post-pandemic high of 33.3%. The figure just for telephone appointments has remained broadly unchanged over this period, at about 25%. Professor Kamila Hawthorne, chairwoman of the Royal College of GPs (RCGP), said: 'Remote consultations, whether delivered over the phone or via video, can offer convenience and flexibility that many patients value, and evidence has shown that in the vast majority of cases, remote care is safe. 'Often a GP might initially consult with a patient remotely and then ask them to come into the practice if it's necessary to see them in person. 'However, we also know that many patients prefer to access their care in-person, and this is how the majority of appointments are still delivered. 'Over the last 12 months, GPs and their teams have delivered a record-breaking number of appointments, and nearly 250 million were carried out in person.' Some 63.3% of GP appointments in June in England were in person, data shows, down from 65.3% a year earlier and 68.4% in June 2023. Online appointments include those carried out using live chat tools or non-video apps, as well as video-based calls. The proportion of appointments taking place by phone or online varies across the regions, with the figures for June ranging from 38.2% in London to 28.4% in North East and Yorkshire. Prof Hawthorne said the college 'supports a mixed-method approach to delivering care' in general practice and decisions on how appointments are carried out are between clinicians and patients. 'What's key is that when GPs are consulting with their patients remotely, they have access to the robust and up-to-date IT systems that allows them to do so safely and effectively,' she added. Prof Hawthorne said the Government 'has put forward some encouraging proposals to improve the GP practice digital infrastructure and IT systems' but 'significant investment' is needed to make this a reality. She added: 'The college has called for additional funding of at least £2 billion to ensure our physical and digital infrastructure is fit for purpose so we can offer patients the appointment that's right for them.' A Department of Health and Social Care spokesperson said: 'We've made real progress fixing the front door of the NHS, recruiting more than 2,000 GPs in the last year and delivering an additional 7 million GP appointments to improve access for patients. 'Through our 10 Year Health Plan we are delivering Neighbourhood Health Services that deliver more personalised, proactive care in local areas where it is more convenient for patients. 'This Government is also clear that patients should have access to health and care when they need it and people who prefer a face-to-face appointment should have one, so we are transforming the NHS app to make managing your healthcare online easy and flexible.' An NHS England spokesperson said: 'Every GP practice must offer face-to-face appointments where patients want or need them, and many patients choose remote appointments where it is clinically appropriate and more convenient for them. 'GP teams are working hard to offer better access for patients, with a record number of appointments being carried out in the last year and recent findings showing the number of patients who are satisfied with their practice has improved.'
The Independent
37 minutes ago
- The Independent
Warning issued to patients who stop using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
The Guardian
38 minutes ago
- The Guardian
Chris Minns stares down backbench revolt over handling of Sydney Harbour Bridge protest
The New South Wales premier, Chris Minns, has stared down a revolt among his backbench over his handling of the weekend march across the Sydney Harbour Bridge, with caucus agreeing to a more moderate motion acknowledging the protests. Members of the right and some of the left faction had sought to move a motion condemning the destruction of Gaza and the 'Israeli government's endorsement of ethnic cleansing of Palestinians from the territory'. It condemned all crimes against against humanity, including genocide, the murder of civilians and hostage taking. The motion also called for a recognition of the right to protest and called on the Minns government to begin work on options for a human rights bill, similar to Victoria. But the motion was effectively removed from consideration by caucus and a far more modest motion, which recognised the scale of the protests, was passed. Sign up: AU Breaking News email About a dozen caucus members voiced their unhappiness at the premier's willingness to block the march and prioritise public safety over the right to protest. In the first two years of his government, Minns has enjoyed very solid support from his party and, through his top-down style, has avoided outbreaks of dissent from his backbench. But the huge public turnout emboldened backbenchers to express their concern about Minns' stance to block the protests. Police estimated 90,000 people took part, while organisers estimated it was closer to 300,000. Meanwhile the NSW opposition put forward a private member's bill in parliament on Tuesday morning to amend the summary offences act, which deals with approving protests. Sign up to Breaking News Australia Get the most important news as it breaks after newsletter promotion The bill proposed to limit each cause to three protests a year, with organisers potentially liable to pay for the costs of policing if more protests were held, unless a court ruled it could go ahead. The opposition leader, Mark Speakman, said that every dollar spent on managing public safety at protests meant police resources were being drained from domestic violence and fighting organised crime. The government declined to support the opposition bill. Prior to the march, 72 organisations, including all major NSW trade unions, civil rights organisations and community groups signed a letter by the Australian Democracy Network calling for the premier to ensure police facilitated the march going ahead, and criticising what they called the premier's anti-protest agenda.
